Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
Candel Therapeutics (Nasdaq: CADL), a clinical stage biopharmaceutical company developing biological immunotherapies for cancer treatment, has announced its participation in the Jefferies London Healthcare Conference 2024.
The company's President and CEO, Paul Peter Tak, will deliver a presentation on Wednesday, November 20, 2024, from 9:30-9:55AM GMT / 4:30-4:55AM EST. The presentation will be accessible via webcast, with a replay available for up to 90 days on the company's website under the Investors section.
Candel Therapeutics (Nasdaq: CADL), un'azienda biofarmaceutica in fase clinica che sviluppa immunoterapie biologiche per il trattamento del cancro, ha annunciato la sua partecipazione alla Jefferies London Healthcare Conference 2024.
Il Presidente e CEO dell'azienda, Paul Peter Tak, terrà un intervento mercoledì 20 novembre 2024, dalle 9:30 alle 9:55 GMT / dalle 4:30 alle 4:55 EST. La presentazione sarà accessibile tramite webcast, con una replica disponibile per un massimo di 90 giorni sul sito web dell'azienda nella sezione Investitori.
Candel Therapeutics (Nasdaq: CADL), una empresa biofarmacéutica en etapa clínica que desarrolla inmunoterapias biológicas para el tratamiento del cáncer, ha anunciado su participación en la Jefferies London Healthcare Conference 2024.
El presidente y CEO de la empresa, Paul Peter Tak, realizará una presentación el miércoles 20 de noviembre de 2024, de 9:30 a 9:55 AM GMT / de 4:30 a 4:55 AM EST. La presentación será accesible a través de una transmisión en vivo, con una repetición disponible durante hasta 90 días en el sitio web de la empresa en la sección de Inversionistas.
캔델 테라퓨틱스 (Nasdaq: CADL)는 암 치료를 위한 생물학적 면역 요법을 개발하는 임상 단계의 생물 의약품 회사로, 제퍼리 리스 런던 헬스케어 컨퍼런스 2024에 참석한다고 발표했습니다.
회사의 회장 겸 CEO인 폴 피터 탁은 2024년 11월 20일 수요일 GMT 기준 9:30-9:55 AM / EST 기준 4:30-4:55 AM에 발표를 할 예정입니다. 발표는 웹캐스트를 통해 접근할 수 있으며, 회사 웹사이트의 투자자 섹션에서 최대 90일 동안 재생 가능합니다.
Candel Therapeutics (Nasdaq: CADL), une entreprise biopharmaceutique en phase clinique développant des immunothérapies biologiques pour le traitement du cancer, a annoncé sa participation à la Jefferies London Healthcare Conference 2024.
Le président et directeur général de l'entreprise, Paul Peter Tak, fera une présentation le mercredi 20 novembre 2024, de 9 h 30 à 9 h 55 GMT / de 4 h 30 à 4 h 55 EST. La présentation sera accessible par webcast, avec un replay disponible pendant 90 jours sur le site web de l'entreprise dans la section Investisseurs.
Candel Therapeutics (Nasdaq: CADL), ein biopharmazeutisches Unternehmen in der klinischen Phase, das biologische Immuntherapien zur Krebsbehandlung entwickelt, hat seine Teilnahme an der Jefferies London Healthcare Conference 2024 angekündigt.
Der Präsident und CEO des Unternehmens, Paul Peter Tak, wird am Mittwoch, den 20. November 2024, von 9:30 bis 9:55 Uhr GMT / von 4:30 bis 4:55 Uhr EST eine Präsentation halten. Die Präsentation wird über einen Webcast zugänglich sein, mit einer Wiederholung, die bis zu 90 Tage lang im Investorenbereich der Unternehmenswebsite verfügbar ist.
- None.
- None.
NEEDHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference 2024, being held on November 19-21, 2024.
Date: Wednesday, November 20, 2024
Time: 9:30-9:55AM GMT / 4:30-4:55AM EST
Webcast Link: https://wsw.com/webcast/jeff315/cadl/1810704
A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on candeltx.com. A replay of the webcast will be archived for up to 90 days following the session date.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently being evaluated in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic ductal adenocarcinoma (PDAC) (phase 2), and localized, non-metastatic prostate cancer (phase 2b and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, including key data readout milestones and presentations; expectations regarding early biological readouts as predictor of clinical response; and expectations regarding the therapeutic benefit of the Company’s programs. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; the Company’s ability to continue as a going concern; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC) including the Company’s most recent Quarterly Report on Form 10-Q filed with the SEC and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
Vice President
ICR Westwicke
CandelPR@icrhealthcare.com
FAQ
When is Candel Therapeutics (CADL) presenting at the Jefferies London Healthcare Conference 2024?
How can I watch Candel Therapeutics (CADL) presentation at the Jefferies Conference?
How long will the replay of Candel Therapeutics (CADL) Jefferies Conference presentation be available?
What type of company is Candel Therapeutics (CADL)?
